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Abstract
Introduction: This study is based on the results from a Belgian expanded access program in which patients with active 
refractory and erosive rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab in combination 
with methotrexate. The objectives of this study were to evaluate the continuation rate of infliximab and its clinical 
effect over a 7-year period and to document the reasons for discontinuation.
Methods: Between 2000 and 2001, 511 patients with severe and refractory RA were enrolled and treated with 
infliximab. After 7 years, apart from routine clinical follow-up, treating rheumatologists were asked to complete a 
questionnaire designed specifically for the present study to evaluate the current therapy with infliximab, the level of 
disease activity (Disease Activity Score in 28 joints [DAS28]) and the reasons for infliximab discontinuation.
Results: After 7 years, 160 of 511 patients (31%) were still on infliximab treatment. The major reasons for infliximab 
discontinuation included lack of efficacy (104 patients), adverse events (107 patients) and elective change of therapy 
(70 patients). The majority of cases of treatment discontinuation for safety reasons occurred during the first 2 years. In 
contrast, discontinuation due to ineffectiveness showed a more constant rate over the 7-year period. Mean DAS for 
patients still on treatment with infliximab decreased from 5.7 (standard error [SE] 0.1) at baseline to 3.0 (SE 0.1) at year 4 
and remained that low until year 7 (3.0 [SE 0.1]). Low disease activity (defined as DAS28 <3.2) was present in 60.9% of 
patients, and 45.5% achieved remission (DAS28 <2.6). DAS28 at the time of treatment discontinuation due to 
ineffectiveness decreased over the 7-year period from 5.6 (SE 0.3) in 2001 to 4.8 (SE 0.3) in 2008.
Conclusions: This observational study revealed that patients who continue to receive infliximab experience sustained 
clinical benefit. The majority of safety issues occurred during the first 2 years of infliximab therapy. We observed that 
the DAS at the time of therapy discontinuation showed a trend to decrease over time.
Introduction
Anti-TNF agents have become standard treatment for
patients with rheumatoid arthritis (RA) refractory to
non-biologic disease-modifying anti-rheumatic drug
(DMARD) therapy. Although there is strong evidence in
support of the short-term efficacy and safety of these
agents [1,2], data from registries and cohorts are
extremely important to evaluate the long-term treatment
effects and safety issues.
Long-term treatment continuation rates reflect safety,
efficacy and compliance with therapy. Infliximab, primar-
ily used in combination with methotrexate (MTX), is a
highly effective therapy for the majority of RA patients.
After an induction scheme with intravenous infliximab
infusions given at weeks 0, 2 and 6, infliximab is typically
administered at a dose of 3 mg/kg every 8 weeks in com-
b i n a t i o n  w i t h  M T X .  H o w e v e r ,  i n c r e a s i n g  t h e  d o s e  o r
shortening the dosing intervals is a common practice and
may differ between countries according to social security
regulations or guidelines and national recommendations
[3].
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Initiated between 2000 and 2001, the Belgian expanded
access program (EAP) cohort is among the largest of that
time, including 511 RA patients treated with infliximab
therapy. The majority of these patients received inflix-
imab at the standard regimen of 3 mg/kg in combination
with MTX. Patients in the EAP could receive infliximab
therapy (provided by Schering-Plough) before the prod-
uct was reimbursed. We aimed to evaluate attrition of inf-
liximab therapy in patients with long-standing refractory
RA over a seven-year period and to document efficacy
and the reasons for discontinuation, including safety
issues.
Materials and methods
Study population
Five hundred and eleven RA patients entered the Belgian
EAP between February 2000 and September 2001. These
were the first Belgian patients to be treated with TNF
blockade outside of a clinical trial setting. After European
Medicines Agency approval of infliximab for the treat-
ment of RA, patients could enter the EAP and receive inf-
liximab, provided by Schering-Plough for free as part of a
Medical Need Program (the Belgian EAP) until the prod-
uct became reimbursable.
Patients were followed at different academic and non-
academic centres. Clinical evaluations performed at each
infliximab infusion included 28 and 66 of 68 swollen and
tender joint counts, erythrocyte sedimentation rate (ESR;
mm/hr), C-reactive protein (CRP) level (mg/L), Health
Assessment Questionnaire (HAQ) [4], physician's global
assessment of disease activity using a visual analogue
scale (VAS; 0 to 100 mm) and patient's global assessment
of disease activity (VAS 0 to 100 mm).
Along with the clinical evaluations performed on the
day of each infusion, all physicians completed an evalua-
tion of the seven-year experience. The evaluation pro-
vided an assessment of patients on therapy . If patients
were withdrawn from infliximab therapy, the following
information was collected: reasons for withdrawal (inef-
fectiveness, safety, elective, death or loss to follow-up),
Disease Activity Score in 28 joints (DAS28) [5,6] at the
latest infliximab infusion, physician's global VAS, HAQ,
CRP level and ESR prior to infliximab withdrawal. Some
baseline characteristics of the cohort are mentioned in
Table 1[7-9]. All patients had long-standing active and
refractory RA, reflected by a mean baseline failure of 3.9
DMARDs and a mean disease duration of 10 years at
baseline.
After an induction regimen of 3 mg/kg at weeks 0, 2
and 6, all patients received maintenance therapy every 8
weeks. From six months onwards, the treating rheuma-
tologist had the option of increasing the dose (typically by
adding an extra vial of 100 mg infliximab) [7,8]. The stan-
dard infliximab dosage of 3 mg/kg every eight weeks was
reinstituted in the majority of patients between June and
September 2002, when infliximab became a reimbursable
medicine in Belgium at the standard dosage of 3 mg/kg
every eight weeks. Due to this reimbursement issue, phy-
sicians had to reinstitute the standard dose of 3 mg/kg,
but if needed, patients could continue receiving addi-
tional vials, provided for free by Schering-Plough.
During the first six months, steroid and MTX doses
were kept stable; doses could be adjusted from six
months onwards.
Ethically approved, written informed consent (Ghent
University Hospital Ethical Committee 99/273) was
obtained from all patients.
Statistical analysis
Statistical methods available in a classical statistical pack-
age (SPSS 17, Chicago, IL, USA) were employed in all
analyses. These included calculation of means with stan-
dard error (SE) of means or medians for continuous vari-
ables and calculation of proportions for dichotomous
variables. Kaplan-Meier curves were constructed after
censoring of data at seven years. Continuation rates of
infliximab therapy were calculated in the intent-to-treat
format (taking into account all 511 patients initially
enrolled in the study).
Results
Continuation rates of infliximab therapy
Of the initial 511 patients enrolled in the study, 507 effec-
tively started infliximab therapy. After seven years, avail-
able data were obtained from 441 patients. Of the
Table 1: Baseline characteristics of the cohort
Female/male (%) 73/27
Age (years) 53 (0.6)
Disease duration (years) 12 (0.4)
Rheumatoid factor positivity (%) 73%
Previous DMARDs (n) 3.9 (0.1)
Swollen joint count (n) 15.2 (0.4)
Tender joint count (n) 20.1 (0.6)
Serum CRP (mg/dL) 29.1 (1.6)
Patient's assessment of pain (VAS, 
0--100 mm)
61.7 (1.0)
Patient's global assessment of 
disease activity (VAS, 0--100 mm)
63.7 (0.9)
Physician's global assessment of 
disease activity (VAS, 0--100 mm)
59.7 (0.9)
Health Assessment Questionnaire 
(score, 0--3)
1.6 (0.0)
CRP: C-reactive protein; DMARDs: disease-modifying anti-
rheumatic drugs; VAS: visual analogue scale.
For continuous variables, mean and standard error are given.Vander Cruyssen et al. Arthritis Research & Therapy 2010, 12:R77
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remaining 441 patients, 160 (36%) were still on infliximab
therapy and 49 (11%) were lost to follow up. Two hundred
eighty-one patients had discontinued therapy: 104 (24%)
due to ineffectiveness, 107 (24%) due to safety issues and
70 (16%) due to elective reasons. Figure 1 shows the flow-
chart of the events in the cohort, Figure 2 shows the
Kaplan-Meier plots of therapy survival over time and Fig-
ures 3, 4 and 5 show how the different reasons for discon-
tinuation contribute to the overall therapy survival rates.
Efficacy of infliximab therapy
Response on infliximab therapy
Of the 160 patients still on therapy at year seven, 61%
showed a low DAS28 (<3.2); 45.5% were in remission
(DAS28 <2.6; Table 2). Of the patients still on infliximab
therapy at year seven, the median physician's VAS score
was 10 (range 0 to 65).
Figure 6 shows the evolution of the DAS over seven
years of infliximab therapy according to the different rea-
sons for discontinuation.
Concomitant medication at year seven
Ninety-four percent of patients still on infliximab at year
seven received concomitant MTX at a median dosage of
12.5 mg/week, which was similar at baseline and in
patients who dropped out. Forty-two percent of patients
received concomitant corticosteroids at a median dosage
of 5 mg/day.
The median dosage of infliximab given at year seven
was 3 mg/kg every eight weeks. Overall, 33% of patients
still on infliximab at year seven received a higher dose,
mostly one additional vial.
Sixteen percent of patients still on infliximab at year
seven received a dose increase between week 30 and Sep-
tember 2002. After the standard dose of 3 mg/kg was
reinstituted from September 2002 onwards, 66% of those
patients could remain on this standard dose; a dose
increase (mostly by adding an extra vial) was needed in
the remaining 33% of patients.
Of patients who did not receive a dose increase at week
30, 34% needed a dose increase at a later time.
Evolution of (non-)acceptable disease activity over time
Between the start of the study and seven years of follow
up, 104 patients discontinued infliximab due to ineffec-
Figure 1 Disposition of patients over seven years. ITT: intent to treat.
Figure 2 Kaplan-Meier plot showing overall therapy survival over 
time for all patients.Vander Cruyssen et al. Arthritis Research & Therapy 2010, 12:R77
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tiveness. Figure 3 shows that discontinuation due to inef-
fectiveness follows a rather linear trend over time. The
remaining disease activity not acceptable to the physician
and leading to discontinuation of therapy showed a trend
to decrease over time. Mean DAS28 at the time of treat-
ment discontinuation due to ineffectiveness evolved over
the seven-year period from 5.6 (SE 0.3) in 2001 to 4.8 (SE
0.3) in 2008.
Elective discontinuation
Seventy patients electively discontinued therapy, mean-
ing that the reason to discontinue infliximab was not
directly related to the product. In cases in which the rea-
son was specified, the majority of patients who discontin-
ued infliximab due to elective reasons attributed the
discontinuation to the wish (patient's or physician's) to
switch to subcutaneous TNF blockers. Figure 5 shows
that most patients discontinued infliximab due to elective
reasons between year three and year four, when a new
subcutaneous TNF blocker (adalimumab) became avail-
able in Belgium.
Also, patients who electively discontinued therapy pre-
viously experienced a good response to infliximab, which
is reflected by the fact that 61.7% of patients had low dis-
ease activity and 46.7% of patients were in remission at
the time of discontinuation.
Safety issues
Description of safety issues
Over seven years of follow up, 107 patients discontinued
infliximab therapy due to safety issues.
Thirty-seven patients discontinued infliximab therapy
due to infections. These included septic arthritis (n = 6),
(recurrent) respiratory tract infections (n = 6), endocardi-
tis (n = 3), sepsis (n = 3), urinary tract infections (n = 3)
and zoster ophthalmica (n = 2). Suspicion of or confirmed
tuberculosis (TB) occurred in six patients, taking into
Figure 3 Kaplan-Meier plot showing therapy survival over time 
for patients discontinuing infliximab due to ineffectiveness.
Figure 4 Kaplan-Meier plot showing therapy survival over time 
for patients discontinuing infliximab due to safety issues.
Figure 5 Kaplan-Meier plot showing therapy survival over time 
for patients discontinuing infliximab due to elective reasons.Vander Cruyssen et al. Arthritis Research & Therapy 2010, 12:R77
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account that most patients started infliximab therapy
before TB screening was advised (end of January 2001).
TB cases are shown in Table 3. Other infections occurred
in an additional eight patients.
Twenty-five patients discontinued therapy due to infu-
sion reactions. There were 19 malignancies: eight lym-
phomas, four breast cancers, two lung cancers, two
ovarian cancers, one colorectal cancer, one thyroid can-
cer and one spinocellular cancer.
Additional safety issues included pericardial effusions
(n = 4), nephritis (n = 2), disease-related complications (n
= 2), polyneuropathy and demyelinating disease (n = 2),
alopecia (n = 2), lung embolism (n = 1), coronary disease
(n = 1), cardiomyopathy (n = 1) and other/non-specified
safety issues (n = 7). Delay or skip of an infusion due to an
infection or in the context of an operation was not con-
sidered as a 'stop due to safety issue'. Only patients who
stopped and did not restart therapy were considered/
available for this analysis.
Description of deaths
In addition to the previously described safety issues, 17
deaths occurred during infliximab therapy. Four patients
died due to cardiac disease (three infarctions, one heart
failure), one patient died due to an abdominal aneurysm,
two patients died due to infections (pneumonia com-
bined with perforating colitis, endocarditis), two patients
died due to pulmonary embolisms, one patient died due
to emphysema, one patient died due to demyelinating
Table 2: Percentage of patients obtaining low disease activity or remission at year 7 at the time of discontinuation
Mean DAS (SE) Low disease activity Remission
At year 7 (still on infliximab) 3.0 (0.1) 60.90% 45.50%
At discontinuation due to 
ineffectiveness
5.2 (0.2) 10.50% 5.30%
At discontinuation due to 
elective reason
2.9 (0.1) 61.70% 46.70%
At discontinuation due to 
safety issue
4.3 (0.7) 33.30% 13.60%
DAS: Disease Activity Score; SE: standard error.
Figure 6 Disease activity score in 28 joints (DAS28) over time in patients enrolled and remaining on infliximab at seven years or discontin-
uing during the observation period. Circle with flags = mean and standard error of DAS 28. ESR: erythrocyte sedimentation rate; IFX: infliximab.Vander Cruyssen et al. Arthritis Research & Therapy 2010, 12:R77
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disease and two patients committed suicide. The reason
for death was not available for four patients.
If patients stopped due to a safety issue, but died later
on (more than two months later), this event was coded as
a safety issue. This was the case for four patients: two
patients with lung cancer and two patients with lym-
phoma.
Evolution of safety issues over time
Figure 4 shows the cumulative frequencies of discontinu-
ation due to safety issues over time. From this curve, we
found that the majority of safety issues leading to discon-
tinuation of infliximab therapy occurred during the first
two years.
Further analysis showed that 50% of infusion reactions
occurred before week 104 and 50% of infections occurred
before week 82.
Discussion
This study describes the seven-year continuation rates,
s a f e t y  a n d  e f f i c a c y  o f  i n f l i x i m a b  i n  a  l a r g e  c o h o r t  o f
patients with severe long-standing refractory RA. Of the
initial 507 patients who started therapy, 49 patients were
lost to follow up after seven years. This is less than 10% of
patients, which is acceptable for interpreting the evalua-
tion of continuation rates, safety and efficacy of therapy.
Of the remaining 441 patients, 160 (36%) were still receiv-
ing infliximab therapy after seven years.
Due to the chronic nature of RA, requiring therapy for
many years, long-term data to evaluate the efficacy and
safety of the compounds are very important. This infor-
mation can be obtained by cohorts or extensions of con-
trolled trials, mostly focusing on one compound [10,11],
or by registries [12-14]. This study could possibly bridge
the gap between extensions of clinical trials and nation-
wide registries: the inclusion criteria of the program were
based on inclusion criteria similar to the daily clinical
practice reimbursement criteria, and less stringent com-
pared with clinical trials. Due to limited time span of
inclusion, this study can be considered as an inception
cohort, which has specific advantages for the analysis of
trends over time, which is more difficult in registries.
Differences in baseline characteristics may be a reason
for heterogeneity between studies. The heterogeneity
between the different studies results in large differences
in retention rates and Kaplan-Meier curves of anti-TNF
therapy survival. The patients presented in this cohort
suffered from severe long-standing disease, which may
differ from that in patients in more recent studies and
registries, in whom disease duration and activity tend to
be less severe [15].
Interestingly, in this study, we were able to evaluate the
different reasons for discontinuation over time. Discon-
tinuation due to ineffectiveness seemed to be quite con-
stant over time, resulting in a linear Kaplan-Meier curve
(Figure 3), whereas discontinuation due to safety issues
was most frequent during the first two years of therapy.
This resulted in a decline of the slope of the curve over
time (Figure 4). Finally, discontinuation due to elective
reasons not directly related to product safety or ineffec-
tiveness was most frequent around year four (Figure 5),
when a new subcutaneous TNF blocker (adalimumab)
became available in Belgium.
Regarding discontinuation, several factors should be
taken into account. First, the acceptance of remaining
disease activity may differ between physicians and
patients and change over time. When patients have failed
Table 3: Description of cases with (suspected) tuberculosis
ID Type Confirmed Start date of 
infliximab
Date of 
symptoms
Screening
75 TB pneumonitis Positive culture 17/04/00 Week 14 ND
211 Peritoneal and 
pulmonary TB
Positive culture 
on BAL
01/09/00 Week 18 ND
217 Suspicion of 
tubercular 
pleuritis
Multiple negative 
cultures
06/09/00 Week 32 ND
227 Suspicion of 
military TB
Multiple negative 
cultures
18/09/00 Year 5 ND
360 Suspicion of GI TB 
adenitis
Granulomatous 
disease on 
pathology, but 
cultures negative
25/01/01 Year 2
(4 March 2003)
ND
408 Suspicion of TB 
pleuritis
Multiple negative 
cultures
19/03/01 Year 3 PPD unk, chest x-ray nl
BAL: bronchoalveolar lavage; GI: gastrointestinal; ND: not done; PPD: purified protein derivative; TB: tuberculosis.Vander Cruyssen et al. Arthritis Research & Therapy 2010, 12:R77
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several therapies and few alternatives are available, one
can assume that more remaining disease activity will be
tolerated. In contrast, when more alternatives become
available, one can assume that less remaining disease
activity will be tolerated, resulting in an earlier start of a
new biologic therapy [13] and earlier switching of thera-
pies. In this study, mean DAS28 at the time of treatment
discontinuation due to ineffectiveness showed a trend to
decrease over time from 5.6 in 2001 to 4.8 in 2008. Sec-
ond, discontinuation due to safety issues may differ
between populations and eras. For example, a large pro-
portion of patients in this cohort started infliximab ther-
apy before general TB screening was recommended. With
mandatory screening, it is possible that some TB cases in
this cohort could have been avoided.
Finally, discontinuation due to elective reasons may be
highly dependent on local situations (eg, reimbursement
rules, national guidelines, access to infusion clinics) and
the availability of new therapeutic options.
Long-term infliximab therapy seems to be efficacious
and safe. More than 60% of patients still on infliximab at
the seven-year follow up had low disease activity, and
more than 45% of patients who continued infliximab
treatment were in remission at year seven. Similarly low
disease activity was observed in patients who discontin-
ued therapy due to elective reasons. Higher levels of dis-
ease activity were observed at the time patients
discontinued therapy due to safety issues or ineffective-
ness.
Most safety issues resulting in therapy discontinuation
occurred during the first two years of therapy. This was
especially true for infusion reactions and infections. The
trend toward a decrease in infection rates in the long
term might be caused by the elimination of subgroups of
patients determined to be at higher risk for infections on
anti-TNF therapy. No unexpected cases of atypical infec-
tions were observed in this cohort.
Unfortunately, a majority of patients had to withdraw
from infliximab therapy. Extrapolating the data from
other registries and compounds (biologics and
DMARDs) [16,17] over 5 to 10 years demonstrated that,
irrespective of the compound, more than half of RA
patients will drop out of therapy. This suggests that fur-
ther research is needed on the optimisation of treatment
strategies in this era, when an increasing number of com-
pounds became available for the treatment of patients
with this chronic disease.
Conclusions
This study describes the seven-year follow up of a cohort
of 511 RA patients with long-standing refractory disease
who were treated with infliximab in combination with
MTX.
After seven years, the majority of patients had to with-
draw from infliximab therapy; one-third of patients who
continued to receive infliximab experienced sustained
clinical benefit: more than 60% of patients still treated
with infliximab had low disease activity, and more than
45% were in remission.
Long-term treatment with infliximab appears to be
safe: therapy discontinuation due to safety issues
occurred mostly during the first two years of infliximab
treatment.
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